Product Profile - Overview

ASMQ to treat Malaria Fixed dose combination of Artesunate + Mefloquine
First new malaria treatment made in Latin America, for Latin America and South East Asia!
Launched in 2008 Developped by an innovative collaboration between DNDi, Brazil and South-East Asia within the FACT Project Consortium Produced by Farmanguinhos/Fiocruz (Brazilian public pharmaceutical company) The 2-in-1 combination ensures that both drugs are taken together in correct proportions Simple and Adapted Regimen for Children and Adults. As Easy as 1-2-3! Adapted Packaging: 3 years shelf life: the longest shelf life of any FDC for malaria. High compliance and low risk of resistance Registered in Brazil in 2008, in India in 2011, and in Malaysia in 2012 Successful South-South technology transfer from Farmanguinhos to Cipla Ltd, India Soon available in other countries in Latin America and Southeast Asia Download ASMQ brochure, January 2011 [636KB] Download ASMQ scientific overview, January 2011 [850KB] Download ASMQ press pack, April 2008 [1.1MB] Read more about ASMQ project		ASMQ News
		Implementation progress ASMQ registered in Malaysia! 100'000 treatments distributed ASMQ soon available in Myanmar
		Recent Scientific PublicationsTropical Medicine & International Health, April2011 Effect of artesunate and mefloquine in combination on the Fridericia corrected QT intervals in Plasmodium falciparum infected adults from ThailandDNDi, January 2011 The transition from artesunate and mefloquine combinations to fixed dose combination and patient uptake
		Recent Events1 December 2011 ASMQ Workshop in the frame of DNDi Partners' Meeting, Rio, Brazil